{"title":"Out-of-pocket fertility preservation expenses: data from a Japanese nationwide multicenter survey.","authors":"Masanori Ono, Yasushi Takai, Miyuki Harada, Akihito Horie, Yidan Dai, Eiji Kikuchi, Mitsuru Miyachi, Tetsuya Yamamoto, Nobuharu Fujii, Hiroaki Kajiyama, Atsushi Manabe, Toshiaki Yasuoka, Shinji Katsuragi, Keiko Mekaru, Tadashi Maezawa, Yuki Horage, Shinsuke Kataoka, Robert Nakayama, Takako Eguchi Nakajima, Fuminori Kimura, Chikako Shimizu, Kohei Sugimoto, Seido Takae, Yasushi Yumura, Hirotaka Nishi, Tatsuro Furui, Ken-Ichirou Morishige, Chie Watanabe, Yutaka Osuga, Nao Suzuki","doi":"10.1007/s10147-024-02614-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The expenses related to fertility preservation or subsequent assisted reproductive treatments are significant for adolescents and young adult patients in Japan's current healthcare system. With fertility preservation becoming more widespread in developed countries, it is expected that these costs will be covered by insurance or subsidies. It is critical for patients, healthcare providers, and the government to know the costs that patients will be responsible for. In Japan, the costs of fertility preservation and subsequent assisted reproductive technology are not covered by insurance, but patients can apply for subsidies from the local and central governments if certain conditions are met. Presently, the above-mentioned costs, as well as the amount paid by the patient, vary by facility. Therefore, it is essential to ensure patients' continued access to necessary medical care despite the associated costs.</p><p><strong>Methods: </strong>In this study, questionnaires were mailed to 186 certified fertility preservation facilities in Japan to assess patients who had undergone fertility preservation or assisted reproduction. The questionnaires were sent between October 27, 2023 and March 31, 2024, with 140 of the 186 facilities responding (response rate: 75.3%).</p><p><strong>Results: </strong>Our findings show that approximately one-third of the costs was borne by the patients.</p><p><strong>Conclusion: </strong>Given these circumstances, sustainable pricing and insurance coverage are necessary for both patients and facilities.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1959-1966"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-024-02614-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The expenses related to fertility preservation or subsequent assisted reproductive treatments are significant for adolescents and young adult patients in Japan's current healthcare system. With fertility preservation becoming more widespread in developed countries, it is expected that these costs will be covered by insurance or subsidies. It is critical for patients, healthcare providers, and the government to know the costs that patients will be responsible for. In Japan, the costs of fertility preservation and subsequent assisted reproductive technology are not covered by insurance, but patients can apply for subsidies from the local and central governments if certain conditions are met. Presently, the above-mentioned costs, as well as the amount paid by the patient, vary by facility. Therefore, it is essential to ensure patients' continued access to necessary medical care despite the associated costs.
Methods: In this study, questionnaires were mailed to 186 certified fertility preservation facilities in Japan to assess patients who had undergone fertility preservation or assisted reproduction. The questionnaires were sent between October 27, 2023 and March 31, 2024, with 140 of the 186 facilities responding (response rate: 75.3%).
Results: Our findings show that approximately one-third of the costs was borne by the patients.
Conclusion: Given these circumstances, sustainable pricing and insurance coverage are necessary for both patients and facilities.
期刊介绍:
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.